Redeye comments on Paxman’s takeover offer to Dignitana, valued at approximately SEK153m, representi...
Redeye comments on Dignitana’s takeover offer from Paxman, valued at SEK153m (SEK1.
Det fjärde kvartalet kom in under våra förväntningar både vad gäller omsättning och marginaler.
Sprint Bioscience has secured 73.9% of a proposed SEK 31.
Q4 EBIT and guidance pre-announced, portfolio return better Conference call failed to ease three key...
Redeye endorses today’s news that Acarix was named the 2025 Digital Innovation Winner by the Global ...
Avslutningen på 2024 var sval och bolaget uppger att marknaden är avvaktande.
Q4: Headline figures pre-announced last week... ...
Biovica continouse to increase 12m rolling IVD test sales in Q3 of SEK 0.
12% EBITA margin target looks doable... ...more uncertainty on the 8% org.
Förvärvet av TrustPlay, med tillhörande teknikportfölj, positionerar Tangiamo i framkant av den växa...
Biovica records IVD test sales in Q3 of SEK 0.74m (460% above Q3 last year) and total sales of SEK 2...
JonDeTechs personalkostnader var 12 procent lägre än Mangolds prognos och övriga kostnader var 4 pro...
New targets: 8% org. growth, 12% EBITA margin, 15% ROCE Growth and margin targets imply 15%/12% upsi...
Received new order from BAE Systems worth SEK 68m We add contribution from new unnamed defence partn...
Cedergrenska AB (”Cedergrenska” eller ”Koncernen”) meddelade den 12 mars 2025 att Koncernen har ingå...
Redeye resumes its coverage of M.O.B.A. Network. We currently see an attractive entry point, followi...
Redeye initiates coverage of RaySearch, a software company offering treatment planning systems for r...
CapMan hosted its CMD event today in Helsinki. The company shared insights into its current state, a...
Messy quarter, but 2025 guidance firm & in line with ABGSCe Minor estimate changes, EBITA -1-2% on '...